- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03602339
Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose (LEADER 75)
LowEr Administered Dose With highEr Relaxivity: Gadovist vs Dotarem (LEADER 75)
The study was conducted to gain knowledge about a new dose of a diagnostic drug that is used for contrast-enhanced Magnetic Resonance Imaging (MRI) of the human central nervous system (CNS). MRI can visualize the anatomy of the body and is used to detect medical conditions. Diagnostic drugs like gadobutrol and gadoterate contain an element called gadolinium that is applied to improve the analysability of MRI-images.
The purpose of this study was to examine if contrast-enhanced MRI using a reduced dose of the gadolinium-based contrast agent gadobutrol delivers images of similar quality to those obtained when a full dose of the gadolinium-based contrast agent gadoterate was used.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study was an open-label, multi-center, comparative, cross-over trial in adult patients with known or highly suspected CNS pathology who were referred for imaging of the CNS.
The primary objective of the study was to demonstrate the non-inferiority of gadobutrol (0.075 mmol/ kg body weight) to gadoterate (0.1 mmol/ kg body weight).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Pierre Benite, France, 69495
- Centre Hospitalier Lyon Sud
-
Strasbourg, France, 67098
- CHU STRASBOURG - Hôpital de Hautepierre
-
-
-
-
Bayern
-
Erlangen, Bayern, Germany, 91054
- Universitätsklinikum Erlangen
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Germany, 18057
- Universität Rostock - Medizinische Fakultät
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04103
- Universitätsklinikum Leipzig AÖR
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
- Universitatsklinikum Schleswig-Holstein (UKSH)
-
Lübeck, Schleswig-Holstein, Germany, 23538
- Universitätsklinikum Schleswig-Holstein / AÖR
-
-
Thüringen
-
Jena, Thüringen, Germany, 07740
- Friedrich-Schiller-Uni. Jena
-
-
-
-
Puglia
-
Andria, Puglia, Italy, 70031
- ASL Provincia di Barletta-Andria-Trani
-
-
Toscana
-
Pisa, Toscana, Italy, 56126
- A.O.U. Pisana
-
-
Veneto
-
Treviso, Veneto, Italy, 31100
- ULSS2 Marca Trevigiana
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
-
Ulsan Gwang''yeogsi
-
Ulsan, Ulsan Gwang''yeogsi, Korea, Republic of, 44033
- Ulsan University Hospital
-
-
-
-
-
Bern, Switzerland, 3010
- Inselspital Universitätsspital Bern
-
-
Aargau
-
Aarau, Aargau, Switzerland, 5001
- Kantonsspital Aarau
-
-
-
-
Lancashire
-
Preston, Lancashire, United Kingdom, PR2 4HT
- Royal Preston Hospital
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Milton S. Hershey Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Known or highly suspected central nervous system (CNS) pathology referred for contrast-enhanced MRI of the CNS.
- Glomerular filtration rate (eGFR) value ≥ 60 mL/min/1.73m2 derived from a serum creatinine result within four weeks prior to the first study MRI.
- Women with negative urine pregnancy test within 1 hour prior to the administration of gadoterate (the first MRI).
Exclusion Criteria:
- No enhancing lesion visible on the gadoterate-enhanced MRI scan.
- Pregnancy or breastfeeding.
- Severe cardiovascular disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1_Suspected CNS-lesion
Patients with suspected or confirmed CNS-lesions underwent unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
|
Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
Other Names:
|
Experimental: Arm 2_Confirmed CNS-lesion
Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) underwent a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.
|
Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
Other Names:
Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Degree of Lesion Contrast Enhancement
Time Frame: Up to 20 days
|
Degree of lesion contrast enhancement is assessed by 3 blinded Readers (Full Analysis Set).
Results are presented as the Average Reader score.
Blinded Readers scored up to 5 lesions using image sequences and a 4-point scale (1 - No = Lesion not enhanced; 2 - Moderate = Lesion weakly enhanced; 3 - Good = Lesion clearly enhanced; 4 - Excellent = Lesion clearly and brightly enhanced).
|
Up to 20 days
|
Lesion Border Delineation
Time Frame: Up to 20 days
|
Lesion border delineation is assessed by 3 blinded Readers (Full Analysis Set).
Results are presented as the Average Reader score.
Blinded readers scored the delineation of up to 5 lesions using image sequences and a 4-point scale (1 - None = No or unclear delineation; 2 - Moderate = Partial delineation; 3 - Good = Almost clear, but incomplete delineation; 4 - Excellent = Clear and complete delineation).
|
Up to 20 days
|
Lesion Internal Morphology
Time Frame: Up to 20 days
|
Lesion internal morphology is assessed by 3 blinded Readers (Full Analysis Set).
Results are presented as the Average Reader score.
Blinded Readers scored the structure and internal morphology of up to 5 lesions using image sequences and a 3-point scale (1 - Poor = Poor visibility; 2 - Moderate = Partial visibility; 3 - Good = Sufficient visibility)
|
Up to 20 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Lesions Identified
Time Frame: Up to 20 days
|
Number of lesions identified (up to 10) detected by 3 blinded Readers.
The mean (SD) number lesions in the Average Reader for gadobutrol and gadoterate in the Full Analysis Set was reported below.
|
Up to 20 days
|
Detection of Malignant Disease
Time Frame: Up to 20 days
|
The 3 Blinded Readers had to evaluate if the diagnosis resulting from the combined images was malignant disease or not. Each blinded Reader provided a malignant yes/no response. This was compared to the final diagnosis provided by the Investigator. The majority of Readers (2 or 3 Readers agree) was used to calculate sensitivity, specificity, and accuracy - eg. Final Diagnosis - Malignant (Reader 1-yes, Reader 2-no, Reader 3-yes --- Majority Reader yes) - this would be a match for sensitivity. The percentage of sensitivity, specificity, and accuracy of detection of malignant disease detected by 3 blinded Readers, gadobutrol versus gadoterate (Full Analysis Set) is reported below for Majority Readers. |
Up to 20 days
|
Confidence in Diagnosis
Time Frame: Up to 20 days
|
Diagnostic confidence detected by 3 blinded Readers, gadobutrol vs gadoterate (Full Analysis Set).
Blinded Readers rated their confidence in diagnosis according to a 4-point scale (1 - Not confident; 2 - Somewhat confident; 3 - Confident; 4 - Very confident).
Results for the Average Reader are reported below.
|
Up to 20 days
|
Image Quality
Time Frame: Up to 20 days
|
Comparison of image quality between gadobutrol and gadoterate detected by 3 blinded Readers (Full Analysis Set).
Blinded Readers assessed the image quality of gadobutrol- and gadoterate-enhanced images (randomly assigned as left [L] and right [R] image positions) according to a 5-point scale (1- Image R is worse; 2 - Image R is slightly worse; 3- Image R is similar; 4 - Image R is slightly better; 5 - Image R is better).
After unblinding of data, the above codes were translated into the following scale: -2 = Gadobutrol image set is worse ; -1 = Gadobutrol image set is slightly worse ; 0 = Image sets are the same ; 1 = Gadobutrol image set is slightly better; 2 = Gadobutrol image set is better.
Results for the Average Reader are reported below.
|
Up to 20 days
|
Contrast Enhancement Utilizing an Exploratory Overall Contrast Enhancement Estimation Algorithm
Time Frame: Up to 20 days
|
Comparison of contrast enhancement utilizing an overall contrast enhancement estimation algorithm (Full Analysis Set).
The exploratory algorithm analyzed the overall enhancement by comparing the axial T1w (longitudinal relaxation time-weighted) enhanced images to the T1w unenhanced images.
|
Up to 20 days
|
Number of Participants With Treatment-emergent Adverse Events
Time Frame: From the first study drug administration up to 24 hours post injection
|
Number of subjects with treatment-emergent adverse events (TEAEs) (Safety Analysis Set).
TEAEs are defined as any AEs that increase in intensity or that are newly developed during the TE period for Study Period 1 or Study Period 2, where TE period for Study Period 1 goes from the first study drug administration in Study Period 1 to 24 hours post-injection, and TE period for Study Period 2 from the first study drug administration in Study Period 2 to 24 hours post-injection.
|
From the first study drug administration up to 24 hours post injection
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19773
- 2018-000690-78 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Magnetic Resonance Imaging
-
BayerCompletedMagnetic Resonance Imaging | Magnetic Resonance AngiographyPoland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
-
Centre Hospitalier Régional Metz-ThionvilleUniversity of LorraineNot yet recruitingMagnetic Resonance ImagingFrance
-
Jessa HospitalActive, not recruitingMagnetic Resonance ImagingBelgium
-
Boston Scientific CorporationCompletedMagnetic Resonance ImagingSpain, Hong Kong, Germany, Israel, United Kingdom, Italy, United States, Malaysia, Belgium
-
Centre Hospitalier Universitaire, AmiensCompletedMagnetic Resonance ImagingFrance
-
MegaPro Biomedical Co. Ltd.CompletedMagnetic Resonance ImagingTaiwan
-
BayerCompletedMagnetic Resonance ImagingJapan
-
BayerCompletedMagnetic Resonance ImagingPhilippines
-
BayerCompletedMagnetic Resonance Imaging | Myocardial Perfusion ImagingSwitzerland, Germany, Austria, Poland
-
Children's Hospital Medical Center, CincinnatiTerminatedMagnetic Resonance Imaging | AnesthesiaUnited States
Clinical Trials on Gadoterate (Dotarem/Clariscan)
-
Loyola UniversityGuerbetUnknown
-
University of ChicagoGuerbetCompletedBreast Cancer | Breast Neoplasms | Breast Diseases | Breast FibroadenomaUnited States
-
GuerbetCompletedCentral Nervous System Diseases | Diagnostic Self EvaluationUnited States, Korea, Republic of, Argentina, Spain, France, Austria, Germany, Brazil, Chile, Italy, United Kingdom
-
GuerbetCompletedMagnetic Resonance ImagingFrance, Austria, Hungary, Poland
-
GuerbetRecruitingBrain Tumor, Recurrent | Brain Tumor, PrimaryItaly, Hungary, Poland
-
GuerbetCompletedPeripheral Arterial DiseaseAustria
-
GuerbetTerminatedHepatocellular CarcinomaKorea, Republic of
-
Phoenix Children's HospitalGuerbetCompletedIntra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRIBrain DiseasesUnited States
-
Massachusetts General HospitalBoehringer IngelheimRecruitingInterstitial Lung DiseaseUnited States
-
GuerbetCompletedType 2 Diabetes Mellitus | Coronary AtherosclerosisKorea, Republic of